NasdaqCM:LXRXPharmaceuticals
Lexicon Pharmaceuticals (LXRX) Nears Key HCM Readout On An Undervalued Narrative
Lexicon Pharmaceuticals (LXRX) recently completed patient randomization in its pivotal Phase 3 SONATA HCM trial of sotagliflozin for obstructive and non obstructive hypertrophic cardiomyopathy, setting up a key clinical readout expected in early 2027.
See our latest analysis for Lexicon Pharmaceuticals.
Against this SONATA HCM milestone, Lexicon Pharmaceuticals’ share price recently closed at US$2.34, with a 90 day share price return of 50.97% and a year to date share price return of 105.26%,...